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Background: Crohn’s disease is a heterogeneous entity. Disease behaviour, characterised as strictur-
ing, penetrating, or non-stricturing non-penetrating, is a clinically important phenotype as it is associ-
ated with complications and need for surgery. It has recently been showed that the behaviour of
Crohn’s disease changes over the course of the disease.
Aim: To assess the association between rapid development of a penetrating or stricturing pattern of
Crohn’s disease and demographic and clinical characteristics as well as NOD2/CARD15 genotype.
Patients and methods: A total of 163 patients with a firm diagnosis of Crohn’s disease and who had
non-penetrating non-stricturing disease at diagnosis were studied. Various demographic and clinical
characteristics as well as antisaccharomyces cerevisiae antibody status and NOD2/CARD15
genotype were documented in these patients. These characteristics were compared in subgroups of
patients according to evolution of disease behaviour five years after diagnosis.
Results: Five years after diagnosis there were 110 (67.5%) patients with non- structuring
non-penetrating disease, 18 (11%) with stricturing disease, and 35 (21.5%) with penetrating disease.
In multivariate analysis, only disease location and number of flares per year were significantly discri-
minant between the three subgroups (p=0.0009 and 0.0001, respectively). Ileal location of the
disease was associated with a stricturing pattern while a high number of flares was associated with a
penetrating pattern. Active smoking was also associated with a penetrating pattern compared with a
non-stricturing non-penetrating pattern only.
Conclusions: Early development of stricturing or penetrating behaviour in Crohn’s disease is
influenced by disease location, clinical activity of the disease, and smoking habit, but not by NOD2/
CARD15 genotype.
Crohn’s disease (CD) is a multifactorial polygenic diseasecharacterised by chronic inflammation of the gastro-intestinal tract.1 Several diagnostic criteria have been
proposed, usually relying on clinical, endoscopic, radiological,
or histological criteria.2–4 So defined however, CD is still a
heterogeneous entity. The disease can present in various
forms, for example depending on its location, its inclination to
develop anatomical complications, or response to treatment.5
Recently, NOD2/CARD15 has been disclosed as the first gene
associated with CD by two independent groups6 7 and rapidly
confirmed by others.8 Three independent mutations within
NOD2/CARD15 (one frameshift mutation (1007fs) and two
missense mutations (R702W and G908R)) have been found to
be associated with CD in Caucasians. However, from recent
data, it appears that only 25–43% of CD patients carry at least
one of the identified NOD2/CARD15 mutations.9–11 These data
confirm and emphasise the heterogeneity of CD. Among the
multiple subphenotypes proposed for CD, age at diagnosis,
location, and pathological behaviour (including development
of penetrating or stricturing lesions) have recently been
considered by a panel of experts as the most relevant and
potentially genetically determined, and were therefore in-
cluded in the newly proposed “Vienna classification” of CD
(table 1).12 NOD2/CARD15 variants have been recently associ-
ated both with young age at onset9 10 13 14 and small bowel
location.9–11 13 15
The behaviour of CD is clinically relevant as it is associated
with the development of complications and need for surgery.
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Abbreviations: CD, Crohn’s disease; ASCA, antisaccharomyces
cerevisiae antibodies; PCR, polymerase chain reaction.
Table 1 Vienna classification of Crohn’s disease
Age at diagnosis A1, <40 years
A2, >40 years
Location* L1, terminal ileum†
L2, colon
L3, ileocolon
L4, upper gastrointestinal tract‡
Behaviour B1, non-stricturing non penetrating
B2, stricturing¶
B3, penetrating§
*Maximum extent at any time before first resection.
†Limited to the terminal ileum with or without spill over into the
caecum.
‡Any disease location proximal to the terminal ileum regardless of
additional involvement.
¶Occurrence of constant luminal narrowing (radiological,
endoscopic, or surgical) with prestenotic dilatation or obstructive
signs, without penetrating disease, at any time in the course of the
disease.
§Occurrence of intra-abdominal or perianal fistulas, inflammatory
masses, and/or abscesses at any time in the course of the disease.
Perianal ulcers, but not skintags, are also included.
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We have recently shown that the behaviour of CD changes over
the course of the disease.16 The majority of patients present
with non- stricturing non-penetrating disease at diagnosis
while after 25 years the majority harbour either a stricturing
or penetrating pattern. This changing behaviour may still be
determined by both genetic and environmental factors that
may influence its inclination and speed of evolution. An
association between a stricturing pattern and NOD2/CARD15
variants has recently been suggested9 17 18 but the NOD2/
CARD15 genotype was not uniformly found as an independ-
ent factor.10 13 19 The only environmental factor clearly associ-
ated with CD is active smoking. Smoking is significantly more
frequent in CD than in healthy controls.20 Smoking has also
been associated with more aggressive disease21 22 but not with
other clinical or biological characteristics, particularly CD
behaviour. Besides smoking, the demographic and clinical
characteristics of the disease, including treatments used, may
influence its changing behaviour. Antisaccharomyces cerevi-
siae antibodies (ASCA) represent the main serological marker
associated with CD.23 24 ASCA have not been definitively asso-
ciated with particular features of CD although an increased
prevalence has been described in small bowel CD25 26 and
higher levels have been suggested in disease with early onset,
as well as fibrostenosing and internal penetrating disease
behaviours.26 Overall, these data suggesting an association
between NOD2/CARD15 or ASCA and disease behaviour are
flawed by different definitions of disease behaviour and by the
absence of consideration of evolution of this behaviour over
time.
The aim of our work was to look for an association between
evolution of CD behaviour, defined according to the validated
Vienna classification, over the first five years after diagnosis on
the one hand and NOD2/CARD15 genotype, smoking habit,




A total of 163 patients with a firm diagnosis of CD according
to the criteria of Lennard- Jones,2 classified as non-stricturing
non-penetrating disease (B1) at diagnosis based on the
Vienna classification,12 and regularly followed at our institu-
tion (CHU Liège, Clinique St Joseph Liège) were studied.
Patients gave informed consent for the study. These patients
formed part of the population in which we previously studied
evolution of CD characteristics over time according to the
Vienna classification.16 For all of these patients, we recorded
age at diagnosis, location and behaviour of the disease at
diagnosis and after five years of evolution. After five years,
according to the Vienna classification, CD was classified as: B3
in the case of intra-abdominal fistulising lesions or the exist-
ence of perianal disease (including abscess, fistula, or Crohn’s
fissure); B2 when significant strictures were present in the
absence of penetrating disease; and B1 in the absence of stric-
turing or penetrating lesions.
Patients were defined as smokers if they smoked at least
seven cigarettes/week and non- smokers if they had never
smoked or had stopped smoking before diagnosis of CD.
Information on smoking was available in 127 patients. Three
of these had stopped smoking after the onset of CD and were
excluded from the analysis.
A familial form of the disease was defined as the presence
of an inflammatory bowel disease in a relative, whatever the
parental degree. This information was collected, asking the
patient whether he had a relative with CD or ulcerative colitis.
If possible, the relative was then personally contacted to con-
firm these data. In case of doubt, the general practitioner or
gastroenterologist in charge of the patient was also contacted.
This information was regularly updated during follow up.
ASCA status was defined in 90 patients for whom we had a
serum sample dating back to the time of diagnosis, by
commercial ELISA (Medipan Diagnostica, Selchow, Ger-
many), according to the manufacturer’s instructions. Investi-
gators who determined ASCA were blinded to the behaviour
of the disease. Patients were considered as ASCA+ when
either ASCA IgA or IgG was present.
The number of flares per year was evaluated retrospectively
based on patient medical notes. A flare was considered when
the physician in charge of the patient (EL, FF, MD, JB) docu-
mented it in the notes and changed the treatment accordingly.
As patients had exclusively non-stricturing non-penetrating
disease, these flares were characterised by a combination of
digestive and general symptoms, including diarrhoea, abdomi-
nal pain, fever, weight loss, worsening of the general physical
condition, or systemic manifestations. The number of flares
was calculated until the development of stricturing or
penetrating disease or over the first five years of the disease for
patients who remained non-stricturing non- penetrating. A
mean number of flares per year was then calculated for every
patient. The information in the medical notes was available
and judged to be reliable for 126 patients.
The number of steroid courses was also determined
retrospectively from patient medical notes. As for flares, the
number of steroid courses was calculated until the develop-
ment of stricturing or penetrating lesions or over the first five
years of the disease for patients remaining non-stricturing
non-penetrating. A mean number of steroid courses per year
was then calculated for every patient. The information in the
medical notes was available and judged to be reliable for 126
patients.
Reliable information on immunosuppressive treatment was
available in 145 patients. Only 24 patients had taken azathio-
prine during the first five years of the disease. Sixteen had
started azathioprine after the development of penetrating dis-
ease. The remaining eight patients received azathioprine
because of steroid dependent or chronic active disease. In
these patients, the number of months of azathioprine
treatment before the development of a penetrating or strictur-
ing disease or over the first five years of the disease for those
who remained non-penetrating non-stricturing was calcu-
lated.
Demographic and clinical characteristics of the patients are
shown in table 2.
NOD2/CARD15 genotyping
In 98 patients, DNA was collected and genotyped for the three
main variants of NOD2/CARD15 that are associated with CD
(OMIM 605956), as previously defined.6 In this initial report,
the nomenclature of mutations was derived from the sequence
of IBD1. This sequence is identical to the smaller open reading
frame of NOD2/CARD15 described by Ogura and colleagues.7
However, an alternative open reading frame, characterised by
a translation initiation site located 81 nucleotides above the
smaller one, was also reported by Ogura et al. Others have
recently proposed this sequence as the sequence-reference for
mutation annotation.8 In order to avoid confusion, we
therefore used this new method of annotation in the study,
which is easily deduced from the initial one by adding 27 to
the initial number of the mutated amino acid.
The missense mutation R702W (ex R675W) (SNP8,
GenBank accession No G67950) was genotyped by an allele
specific polymerase chain reaction (PCR) procedure. After
amplification (primers: 5′-ATC TGA GAA GGC CCT GCT CC-3′
(wild-type, forward), 5′- ATC TGA GAA GGC CCT GCT CT-3′
(mutated, forward), and 5′-CCC ACA CTT AGC CTT GAT
G-3′(reverse), annealing temperature 58°C, 30 cycles), the PCR
products were loaded on a 2% agarose gel with internal
controls. Genotypes were directly deduced from the migration
profiles. The missense mutation G908R (ex G881R) (SNP12,
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GenBank accession No G67951) was genotyped by a
PCR-restriction fragment length polymorphism procedure. In
brief, after PCR (primers: 5′-CCCAGCTCCTCCCTCTTC-3′ and
5′- AAGTCTGTAATGTAAAGCCAC-3′, annealing temperature
55°C, 30 cycles) the 380 bp products were digested by the
restriction enzyme Hha1 (Gibco BRL) and electrophoresed on
a 2% agarose gel. The profile of the G908R variant was charac-
terised by two bands (138 bp and 242 bp, respectively). For the
frameshift mutation 1007fs (SNP13, GenBank accession No
G67955), PCR products using fluorescently labelled primers
(5′- GAATGTCAGAATCAGAAGGG-3′ and 5′-
CTCACCATTGTATCTTCTTTTC-3′, annealing temperature 55°C,
30 cycles) were loaded on a 377 ABI Prism automatic
sequencer. Genotypes were deduced from the sizes of the PCR
products: 230 bp (wild-type) and 231bp (1007fs, ex 980fs).
Investigators who determined NOD2/CARD15 genotypes were
blinded to the behaviour of the disease.
Statistical analysis
Statistical analyses were performed using SAS 6.12 software.
We initially used univariate analysis to study the association
between evolution of disease behaviour (determined by
disease behaviour five years after diagnosis—B1, B2, or B3)
and each of the described factors, using either a χ2 or Kruskal-
Wallis test, as required. In addition, a subgroup analysis was
performed for patients who became B3 (penetrating disease):
these patients were subdivided into intra-abdominal penetrat-
ing disease and perianal penetrating disease.
A multivariate analysis was then performed using stepwise
discriminant analysis. This multivariate analysis was per-
formed on a subgroup of 83 patients for whom we had
complete data. A p value <0.05 was considered significant.
RESULTS
Disease behaviour evolution
After five years of evolution, the behaviour of CD was classified
as still non-stricturing non-penetrating (B1) in 110 patients
(67.5%), stricturing (B2) in 18 patients (11.0%), and
penetrating (B3) in 35 patients (21.5%). Demographic and
clinical characteristics, as well as NOD2/CARD15 genotype
and ASCA status in these subgroups are showed in table 3.
Association between evolution of CD behaviour (B1,
B2, or B3) and demographic, clinical, and biological
characteristics: univariate analysis
In univariate analysis, disease location, number of flares per
year, number of steroid courses per year, and ASCA status were
significantly different between the three groups, while smok-
ing and familial form were borderline for significance (table
3). There was no association between NOD2/CARD15 geno-
type (defined as variant carriers or not, or as wild- type, sim-
ple heterozygotes, compound heterozygotes, and homozy-
gotes) and evolution of CD behaviour (table 3). There was no
association between various NOD2/CARD15 variants and evo-
lution of CD behaviour.
Association between evolution to subtypes of
penetrating disease (B3) and demographic, clinical,
and biological characteristics: univariate analysis
When intra-abdominal and perianal penetrating disease were
analysed separately, significant differences were found.
Location at diagnosis differed significantly between these
groups, with proportions of L1, L2, L3, and L4 being 83.3%,
8.3%, 8.3%, and 0%, and 13.3%, 40%, 40%, and 6.7% in intra-
abdominal and perianal penetrating disease, respectively
(p=0.004). When perianal penetrating diseases were excluded
from the group of penetrating disease (B3), the association
between location of disease and disease behaviour was still
significant (p<0.0001). Smoking was significantly more
frequent in perianal (86.7%) than in intra-abdominal (45.5%)
penetrating disease (p=0.03). However, the association
between smoking and evolution of disease behaviour was still
borderline significant when perianal penetrating disease was
excluded from the group of penetrating disease (p=0.057). No
other significant difference was found between intra-
abdominal and perianal penetrating disease. As regards the
association between evolution of disease behaviour and clini-
cal, demographic, or biological characteristics, when those
with perianal penetrating disease were excluded from the
group of penetrating disease, apart from location of disease
and smoking habit, the association also remained significant
for the number of flares per year (still higher in penetrating
disease (p=0.001)) while there was no significant association
for the other parameters.
Association between evolution of disease behaviour
(B1, B2, B3) and demographic, clinical, and biological
characteristics: multivariate analysis
In multivariate analysis, only location of disease and number
of flares per year were selected when comparing the three
groups (p values for these parameters in the model were
0.0009 and 0.0001, respectively; the p value of the model was
0.0001). When patients who became B2 were compared with
those who remained B1, only disease location was selected (p
value of the model 0.0001). When patients who became B3
were compared with those who remained B1, both the number
of flares per year and smoking were selected (p values of these
parameters in the model were 0.0001 and 0.02, respectively;
the p value of the model was 0.0001). Finally, when patients
who became B2 were compared with those who became B3,
the number of flares per year, location, and existence of a
familial form of the disease were selected (p values of these
parameters in the model were 0.0004, 0.001, and 0.04, respec-
tively; the p value of the model was 0.0001).
DISCUSSION
We previously showed that CD behaviour changed over the
course of the disease.16 Theoretically, both genetic and
environmental factors could influence this changing behav-
iour. The present data indicate that evolution of disease
behaviour over the first five years is influenced by disease
Table 2 Characteristics of the patients
Age at diagnosis (%) (n=163)
<40 years (A1) 85.4
>40 years (A2) 14.6








Smoking habit (%) (n=124)
Yes 52.4
No 47.6









Steroid courses (No/year) (n=126) 0.4 (0.53)*
Flares of CD (No/year) (n=126) 0.89 (0.8)*
Azathioprine treatment (months/year) (n=145) 0.25 (0.1)*
CD, Crohn’s disease; ASCA, antisaccharomyces cerevisiae
antibodies.
*Mean (SD).
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location, number of flares per year, and smoking habit, but not
by NOD2/CAD15 genotype.
The behaviour of CD represents a major characteristic of the
disease. Penetrating and stricturing phenotypes are associated
with the development of complications and need for surgery.
An attempt to identify markers or factors that are associated
with these phenotypes is motivated by the need to predict this
behaviour to be able to select patients for appropriate early
management. Such an association between phenotype and
clinical, demographic, or genetic factors may also help to
understand the mechanisms underlying phenotype develop-
ment. Studies on disease behaviour have been hampered by
the variability of classifications used27–29 and by their unsatis-
factory degree of inter-rater agreement.30 More recently, the
Vienna classification has been proposed which aims to stratify
patients on the basis of widely accepted and reproducible
criteria.12 Its reproducibility has recently been confirmed to be
good.31 A certain degree of constancy of disease behaviour has
been suggested by some authors on the basis of surgical
indications.27 32 33 The significantly conserved behaviour in
multiply affected families has also suggested that this behav-
iour could be at least partly genetically determined.34–36
However, using the Vienna classification, and carefully
reviewing the medical history of individual patients, we have
demonstrated a dramatic change in disease behaviour over the
course of the disease.16 This is not necessarily in contradiction
with previous studies but indicates that the disease behaviour
of CD cannot be analysed without taking into account the
duration of disease. After a certain duration of disease
however, some characteristics of disease behaviour may be
more stable or even fixed.16 To analyse the factors potentially
involved in disease behaviour determinism, we studied a
homogeneous population of uncomplicated disease (B1) at
diagnosis and over a predefined duration of follow up. We
looked at rapid development of penetrating or stricturing dis-
ease (within five years) to identify factors strongly influencing
the development of such complications.
The two main factors independently associated with change
in disease behaviour within five years after diagnosis were
ileal location of the disease and number of flares per year. Ileal
location was essentially associated with the development of
stricturing disease and was not a discriminant factor between
penetrating disease and non-stricturing non-penetrating dis-
ease when only these two phenotypes were compared.
However, when penetrating disease was divided into intra-
abdominal and perianal disease, ileal location was signifi-
cantly more frequent in intra-abdominal than perianal
penetrating disease and it reached, in the first subgroup, a fre-
quency similar to that observed in stricturing disease. This
association between stricturing disease or intra-abdominal
penetrating disease and ileal location has been described in
studies of disease behaviour based on surgical series, irrespec-
tive of the duration of disease.27 37 One explanation for the
association with stricturing disease may be the smaller diam-
eter of the gut lumen in the ileum than in the colon, making
functionally significant strictures more likely to occur.
Another explanation could be the nature of the immuno-
inflammatory reaction in the ileum compared with the colon,
but such a difference has not yet been clearly demonstrated,
although the number of Peyer’s patches is greater in the ileum
than in the colon and may influence the mucosal immuno-
inflammatory reaction.38 The development of intra-abdominal
penetrating lesions may in itself be favoured by downstream
strictures in a subset of patients.39 A high number of flares of
the disease per year was essentially associated with the devel-
opment of penetrating disease (intra-abdominal as well as
perianal penetrating disease) and was not a discriminant fac-
tor between stricturing and non-stricturing non-penetrating
disease when only these two phenotypes were compared.
Again, this is not unexpected as penetrating disease is often a
Table 3 Demographic, clinical, and biological parameters depending on Crohn’s disease behaviour*
B1 B2 B3 p Value
Age at diagnosis (%) (n=163) n=110 n=18 n=35
<40 years (A1) 82.0 88.9 94.3 0.18
>40 years (A2) 18.0 11.1 5.7
Location of the disease (%) (n=163) n=110 n=18 n=35
Ileal (L1) 38.2 89.9 45.7 0.0003
Colonic (L2) 33.6 0 22.9
Ileocolonic (L3) 23.6 0 28.6
Upper gastrointestinal tract (L4) 4.6 11.1 2.9
Sex (%) (n=163) n=110 n=18 n=35
Male 34.5 22.2 37.1 0.53
Female 65.5 77.8 62.9
Smoking habit (%) (n=124) n=79 n=16 n=29
Yes 41.8 62.5 65.5 0.052
No 58.2 37.5 34.5
Familial disease (%) (n= 156) n=106 n=16 n=34
Yes 17.0 31.3 5.9 0.07
No 83.0 68.7 94.1
ASCA (%) (n=90) n=54 n=14 n=22
Positive 64.8 35.7 72.7 0.044
Negative 35.2 64.3 27.3
NOD2/CARD15 (%) (n=101) n=48 n=18 n=35
Wild-type 47.9 44.4 68.6 0.34
Heterozygotes 39.6 38.9 22.8
Homozygotes and compound heterozygotes 12.5 16.7 8.6
Steroid courses (No/year) (n=126) n=83 n=15 n=28
0.35 (0.48)* 0.23 (0.26)* 0.69 (0.71)* 0.026
Flares of CD (No/year) (n=126) n=83 n=15 n=28
0.74 (0.77)* 0.68 (0.22)* 1.53 (0.82)* <0.0001
Azathioprine treatment (months/year) (n=145) n=99 n=16 n=30
0.25 (0.12)* 0.4 (0.4)* 0.16 (0.16)* 0.84
*B1, non-stricturing non-penetrating; B2, stricturing; B3, penetrating, according to the Vienna classification, five years after diagnosis.
p values correspond to univariate analysis for each parameter using either χ2 or Kruskal Wallis tests, as required.
CD, Crohn’s disease; ASCA, antisaccharomyces cerevisiae antibodies.
*Mean (SD).
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clinically more aggressive disease. The development of
penetrating lesions could be a consequence of the severity of
the inflammatory reaction at the mucosal level. In contrast,
stricturing disease can often be silent for a long time,
manifesting only when the stricture has developed.
Active smoking was more frequent in patients who
developed penetrating but also stricturing disease. It was
independently associated with the development of penetrat-
ing disease when patients who developed penetrating disease
and patients who remained non- stricturing non-penetrating
were compared. This association between smoking and
penetrating disease was particularly pronounced for perianal
penetrating disease. Smoking has previously been associated
with more aggressive CD21 22 but not specifically with
penetrating or perianal complications. The effect of smoking
could have been related to an effect on disease severity and
number of flares. This association was however independent
in the present study. The mechanism by which smoking may
favour penetrating lesions, as well as more aggressive disease,
remains to be elucidated.
Globally, as previously discussed, factors associated with
intra-abdominal or perianal penetrating disease are not the
same. Indeed, if a more aggressive disease (defined by the
annual number of flares) seems to be associated with both
subtypes of penetrating disease, it is not the case for ileal loca-
tion, essentially associated with intra-abdominal penetrating
disease, or for active smoking, more associated with perianal
disease. These data suggest mechanisms at least partly differ-
ent for the development of these two types of penetrating dis-
ease. Furthermore, in our series, only a small minority of
patients harboured both intra- abdominal and perianal
penetrating disease. Therefore, they maybe represent distinct
entities and should perhaps be studied independently.
When patients who developed stricturing and those who
developed penetrating lesions were compared, independent
discriminating factors were the number of flares (higher in
penetrating disease, as already discussed) and ileal location, as
well as the familial form of the disease (more frequent in
patients who developed stricturing lesions). The association
between stricturing disease and familial disease has already
been described but was thought to be mainly linked to ileal
location and early age at onset.40 Interestingly, a familial
history of the disease was associated with stricturing
behaviour in our study independent of ileal location or age at
onset.
In the univariate analysis, ASCA were significantly more
frequent in patients with penetrating lesions. An association
had already been suggested between ASCA and the penetrat-
ing phenotype.26 In the present study however, this association
was not independent, indicating that ASCA status does not
represent a significant marker associated with disease behav-
iour. A similar conclusion can be drawn for steroid use, associ-
ated in the univariate analysis with penetrating behaviour but
no longer present after multivariate analysis. This is probably
due to the correlation between the number of flares
independently associated with disease behaviour and steroid
use. With regard to treatment, we found no association
between immunosuppressive treatment and disease behav-
iour. Very few patients were receiving immunosuppressive
treatments however, mainly because we studied the early
phase of the disease up to five years after diagnosis and
because immunosuppressive treatments are often started
after the development of penetrating lesions. The influence of
immunosuppressive treatments or biotherapies on disease
behaviour should be an area of study in a larger sample of
treated patients.
Importantly, in this study we found no association between
NOD2/CARD15 variants and disease behaviour. This is in con-
trast with reported studies.9 10 17–19 However, in those previous
studies, results were partly discordant, criteria used to classify
disease behaviour were inhomogeneous, and duration of dis-
ease before definition of disease behaviour was not taken into
account. It must also be emphasised that the recently
documented association between NOD2/CARD15 mutations
and ileal location may induce secondary association with
stricturing behaviour.10 Therefore, we believe that these previ-
ous data are inconclusive. Our study is the first to have
carefully analysed this point, with a validated classification,
and we can conclude that there is no major influence of
NOD2/CARD15 genotype on CD behaviour. However, we can-
not exclude a small influence, acting slowly and having an
impact on disease behaviour after a longer period of time. This
should be tested in an adequately designed study.
In conclusion, we have shown that ileal location of CD and
aggressive disease with a high number of flares were
independently associated with rapid development of strictur-
ing and penetrating disease, respectively. Smoking habit was
also significantly associated with the development of pen-
etrating behaviour while there was no association between
NOD2/CARD15 genotype and evolution of disease behaviour.
When studying potential associations between genetic mark-
ers and disease behaviour in CD, patients should be stratified
according to disease location, disease aggressiveness, and also
probably smoking habit.
ACKNOWLEDGEMENTS
E Louis is a Research Associate at the FNRS Belgium
. . . . . . . . . . . . . . . . . . . . .
Authors’ affiliations
E Louis, V Michel, C Reenaers, F El Yafi, J Belaiche, Department of
Gastroenterology, University Hospital of Liège, Belgium
J P Hugot, Fondation Jean Dausset CEPH, Paris, France
F Fontaine, M Delforge, Department of Gastroenterology, Clinique St
Joseph Liège, Belgium
J F Colombel, Department of Gastroenterology, CHU Lille, France
REFERENCES
1 Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis.
Gastroenterology 1998;115:182–205.
2 Lennard-Jones JE. Classification of inflammatory bowel disease. Scand
J Gastroenterol Suppl 1989;24:2–6.
3 Gower-Rousseau C, Salomez JL, Dupas JL, et al. Incidence of
inflammatory bowel disease in Northern France (1988–1990). Gut
1994;35:1433–8.
4 Jenkins D, Balsitis M, Gallivan S, et al. Guidelines for the initial biopsy
diagnosis of suspected chronic idiopathic inflammatory bowel disease.
The British Society of Gastroenterology Initiative. J Clin Pathol
1997;50:93–105.
5 Sutherland LR. Different patterns of Crohn’s disease. In: Prantera C,
Korelitz B, eds. Crohn’s Disease. New York: Marcel Dekker Inc,
1996:201–15.
6 Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2
leucin-rich repeat variants with susceptibility to Crohn’s disease. Nature
2001;411:599–603.
7 Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2
associated with susceptibility to Crohn’s disease. Nature
2001;411:603–6.
8 Hampe J, Cuthbert A, Crouche PJP, et al. Association between insertion
mutation in NOD2 gene and Crohn’s disease in German and British
population. Lancet 2001;357:1925–8.
9 Lesage S, Zouali H, Cezard JP, et al. CARD15/NOD2 mutational
analysis and genotype-phenotype correlation in 612 patients with
inflammatory bowel disease. Am J Hum Genet 2002;70:845–57.
10 Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the
manifestations of Crohn’s disease. Gastroenterology 2002;122:854–66.
11 Cuthbert AP, Fisher SA, Mirza MM, et al. The contribution of NOD2
gene mutations to the risk and site of disease in inflammatory bowel
disease. Gastroenterology 2002;122:867–74.
12 Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of
Crohn’s disease: report of the working party of the world congresses of
gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000;6:8–15.
13 Louis E, Hugot JP, Colombel JF, et al. NOD2/CARD15 mutations in
Crohn’s disease are associated with young age at diagnosis and ileal
location. Gastroenterology 2002;122(suppl):M1405.
14 Eri RD, Pandeya N, Purdie D, et al. Frequency and association of the
3020INSC insertion in the NOD2 Crohn disease susceptibility gene in a
well-characterized patient cohort. Gastroenterology
2002;122(suppl):M1410.
15 Vermeire S, Esters N, Pierik M, et al. Detailed study on phenotypical
associations of NOD2/CARD15 mutations in Crohn’s disease.
Gastroenterology 2002;122(suppl):M1413.
556 Louis, Michel, Hugot, et al
www.gutjnl.com
16 Louis E, Collard A, Oger AF, et al. Behaviour of Crohn’s disease
according to the Vienna classification: changing pattern over the course
of the disease. Gut 2001;49:777–82.
17 Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated
with fibrostenosing disease in patients with Crohn’s disease.
Gastroenterology 2002;123:679–88.
18 Radlmayr M, Török HP, Martin K, et al. The c-insertion mutation of the
NOD2 gene is associated with fistulizing and fibrostenotic phenotypes in
Crohn’s disease. Gastroenterology 2002;122:2091–2.
19 Hampe J, Grebe J, Nikolaus S, et al. Association of NOD2 (CARD15)
genotype with clinical course of Crohn’s disease cohort study. Lancet
2002;359:1661–5.
20 Calkins BM. A meta-analysis of the role of smoking in inflammatory
bowel disease. Dig Dis Sci 1989;34:1841–54.
21 Sutherland LR, Ramcharan S, Bryant H, et al. Effect of cigarette smoking
on recurrence of Crohn’s disease. Gastroenterology 1990;98:1123–8.
22 Cosnes J, Carbonnel F, Beaugerie L, et al. Effects of smoking on the long
term course of Crohn’s disease. Gastroenterology 1996;110:424–31.
23 Main J, McKenzie H, Yeaman GR, et al. Antibody to Saccharomyces
cerevisiae (bakers’ yeast) in Crohn’s disease. BMJ 1988;297:1105–6.
24 Sendid B, Colombel JF, Jacquinot PM, et al. Specific antibody response
to oligomannosidic epitopes in Crohn’s disease. Clin Diagn Lab Immunol
1996;3:219–26.
25 Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae
mannan antibodies combined with anti-neutrophil cytoplasmic antibodies
in inflammatory bowel disease: prevalence and diagnostic role. Gut
1998;42:788–91.
26 Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression
stratifies Crohn’s disease into immunologically homogeneous subgroups
with distinct clinical characteristics. Gut 2000;47:487–96.
27 Greenstein AJ, Lachman P, Sachar DB, et al. Perforating and
non-perforating indications for repeated operations in Crohn’s disease:
evidence for two clinical forms. Gut 1988;29:588–92.
28 Sachar DB, Andrews HA, Farmer RG, et al. Proposed classification of
patient subgroups in Crohn’s disease. Gastroenterol Int 1992;5:141–54.
29 Greenway SE, Buckmire MA, Marroquin C, et al. Clinical subtypes of
Crohn’s disease according to surgical outcome. J Gastrointest Surg
1999;3:145–51.
30 Steinhart AH, Girgrah N, McLeod RS. Reliability of a Crohn’s disease
clinical classification scheme based on disease behavior. Inflamm Bowel
Dis 1998;4:228–34.
31 Achkar JP, Brzezinski A. Interobserver agreement for disease behaviour
phenotype in Crohn’s disease. Gastroenterology
2002;122(suppl):W1293.
32 Lautenbach E, Berlin JA, Lichtenstein GR. Risk factors for early
postoperative recurrence of Crohn’s disease. Gastroenterology
1998;115:259–67.
33 Yamamoto T, Allan RN, Keighley MR. Perforating ileocaecal Crohn’s
disease does not carry a high risk of recurrence but usually re-presents as
perforating disease. Dis Colon Rectum 1999;42:519–24.
34 Peeters M, Nevens H, Baert F, et al. Familial aggregation in Crohn’s
disease: increased age-adjusted risk and concordance in clinical
characteristics. Gastroenterology 1996;111:597–603.
35 Bayless TM, Tokayer AZ, Polito JM II, et al. Crohn’s disease:
concordance for site and clinical type in affected
family-members-potential hereditary influences. Gastroenterology
1996;111:573–9.
36 Satsangi J, Grootscholten C, Holt H, et al. Clinical patterns of familial
inflammatory bowel disease. Gut 1996;38:738–41.
37 Farmer RG, Hawk WA, Turnbull RB Jr. Indications for surgery in Crohn’s
disease. Gastroenterology 1976;71:245–50.
38 Van Kruiningen HJ, Ganley LM, Freda BJ. The role of Peyer’s patches
in the age- related incidence of Crohn’s disease. J Clin Gastroenterol
1997;24:470–5.
39 Kelly JK, Preshaw RM. Origin of fistulas in Crohn’s disease. J Clin
Gastroenterol 1989;11:193–6.
40 Colombel JF, Grandbastien B, Gower-Rousseau C, et al. Clinical
characteristics of Crohn’s disease in 72 families. Gastroenterology
1996;111:604–7.
Factors influencing early development of stricturing or penetrating Crohn’s disease 557
www.gutjnl.com
